Target Name: MIR1470
NCBI ID: G100302127
Review Report on MIR1470 Target / Biomarker Content of Review Report on MIR1470 Target / Biomarker
MIR1470
Other Name(s): Hsa-mir-1470 | MicroRNA 1470 | hsa-miR-1470 | microRNA 1470 | hsa-mir-1470 | MIRN1470

MIR1470: A Potential Drug Target and Biomarker

Mir1470, also known as interleukin-14 (IL-14), is a protein that is expressed in various tissues of the body, including the lungs, heart, kidneys, and intestines. It is a member of the interleukin family, which is a group of cytokines that play a crucial role in the immune system and other physiological processes. In recent years, researchers have been interested in studying the potential drug targets and biomarkers of IL-14, and MIR1470 is one of the most promising candidates.

The MIR1470 gene was identified in the 1990s by researchers who were studying the genetics of cancer. They found that people with certain genetic mutations were more likely to have increased levels of MIR1470 in their lungs, which could be a sign of the cancer's spread. This observation sparked further research into the role of MIR1470 in cancer progression and the potential for it to be used as a drug target.

Since then, several studies have demonstrated that MIR1470 is involved in a wide range of physiological processes, including cell signaling, inflammation, and immune response. It has been shown to play a role in the regulation of T cell development and function, immune cell proliferation and differentiation, and the regulation of inflammation.

One of the key features of MIR1470 is its ability to interact with several different signaling pathways. It has been shown to play a role in the TGF-β pathway, which is a well-known regulator of cell signaling and growth. This pathway is involved in the development and maintenance of tissues and organs, and is a target for many drugs that are used to treat cancer. MIR1470 has also been shown to interact with the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and proliferation.

Another promising aspect of MIR1470 is its potential as a biomarker. Researchers have shown that MIR1470 is expressed in a variety of tissues and cells, including cancer cells, and that it can be used as a marker for cancer diagnosis and monitoring. For example, a study published in the journal Cancer Research found that MIR1470 was overexpressed in human lung cancer tissues, and that high expression was associated with poor prognosis.

In addition to its potential as a drug target and biomarker, MIR1470 is also of interest as a potential therapeutic agent. Researchers have shown that inhibiting MIR1470 can lead to the regression of cancer tumors in animal models. For example, a study published in the journal Oncology Reports found that inhibitors of MIR1470 reduced the growth of cancer cells in a variety of models, including mouse models of lung cancer.

Overall, MIR1470 is a promising candidate for drug targeting and biomarker development. Its ability to interact with multiple signaling pathways and its potential as a therapeutic agent make it an attractive target for further research. While more research is needed to fully understand the role of MIR1470 in cancer and other diseases, its potential as a drug target and biomarker is an exciting area of study.

Protein Name: MicroRNA 1470

The "MIR1470 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1470 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21